CU20220041A7 - Dispersión sólida amorfa de 8-cloro-n-(4-(trifluorometoxi)fenil)quinolin-2-amina - Google Patents
Dispersión sólida amorfa de 8-cloro-n-(4-(trifluorometoxi)fenil)quinolin-2-aminaInfo
- Publication number
- CU20220041A7 CU20220041A7 CU2022000041A CU20220041A CU20220041A7 CU 20220041 A7 CU20220041 A7 CU 20220041A7 CU 2022000041 A CU2022000041 A CU 2022000041A CU 20220041 A CU20220041 A CU 20220041A CU 20220041 A7 CU20220041 A7 CU 20220041A7
- Authority
- CU
- Cuba
- Prior art keywords
- quinolin
- trifluoromethoxy
- chloro
- amine
- phenyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Colloid Chemistry (AREA)
Abstract
<p>La presente invención se refiere a una dispersión sólida amorfa, caracterizada porque comprende 8-cloro-N-( 4-(trifluorometoxi)fenil)quinolin-2-amina, útil en el tratamiento y/o prevención de enfermedades inflamatorias, enfermedades causadas por virus y/o cáncer o displasia.</p> <p>Se refiere también al proceso de preparación de Ia misma y a Ia composición farmacéutica que Ia contiene.</p>
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20305089.3A EP3858336A1 (en) | 2020-01-31 | 2020-01-31 | Amorphous solid dispersion of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine |
EP20306410 | 2020-11-19 | ||
PCT/EP2021/052163 WO2021152129A1 (en) | 2020-01-31 | 2021-01-29 | Amorphous solid dispersion of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine |
Publications (1)
Publication Number | Publication Date |
---|---|
CU20220041A7 true CU20220041A7 (es) | 2023-03-07 |
Family
ID=74505233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CU2022000041A CU20220041A7 (es) | 2020-01-31 | 2021-01-29 | Dispersión sólida amorfa de 8-cloro-n-(4-(trifluorometoxi)fenil)quinolin-2-amina |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230218605A1 (es) |
EP (1) | EP4096640A1 (es) |
JP (1) | JP2023532163A (es) |
KR (1) | KR20220134569A (es) |
CN (1) | CN115279345A (es) |
AU (1) | AU2021213321A1 (es) |
BR (1) | BR112022014772A2 (es) |
CA (1) | CA3164700A1 (es) |
CU (1) | CU20220041A7 (es) |
IL (1) | IL294850A (es) |
MX (1) | MX2022009019A (es) |
WO (1) | WO2021152129A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11590122B2 (en) | 2021-02-19 | 2023-02-28 | Slayback Pharma Llc | Pharmaceutical compositions of cabozantinib |
KR20230163394A (ko) | 2021-03-01 | 2023-11-30 | 디시듀어스 세러퓨틱스 인코포레이티드 | 불변 자연 살해 t-세포를 활성화하기 위한 화합물 및 염증 노화 세포를 제거하는 데 사용하는 방법 |
EP4215196A1 (en) * | 2022-01-24 | 2023-07-26 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030216398A1 (en) * | 2001-04-05 | 2003-11-20 | Mitsuru Kakihana | Soluble beta amyloid precursor protein secretion promoters |
CN106905232B (zh) | 2009-06-12 | 2019-09-27 | Abivax公司 | 用于治疗过早衰老和尤其是早衰的化合物 |
CN110996983A (zh) * | 2017-06-26 | 2020-04-10 | 巴斯德研究所 | 清除hiv储库并降低病毒载量的治疗 |
-
2021
- 2021-01-29 CA CA3164700A patent/CA3164700A1/en active Pending
- 2021-01-29 EP EP21702950.3A patent/EP4096640A1/en active Pending
- 2021-01-29 JP JP2022546122A patent/JP2023532163A/ja active Pending
- 2021-01-29 CN CN202180017830.3A patent/CN115279345A/zh active Pending
- 2021-01-29 MX MX2022009019A patent/MX2022009019A/es unknown
- 2021-01-29 CU CU2022000041A patent/CU20220041A7/es unknown
- 2021-01-29 WO PCT/EP2021/052163 patent/WO2021152129A1/en unknown
- 2021-01-29 US US17/796,834 patent/US20230218605A1/en active Pending
- 2021-01-29 BR BR112022014772A patent/BR112022014772A2/pt unknown
- 2021-01-29 KR KR1020227027930A patent/KR20220134569A/ko active Search and Examination
- 2021-01-29 AU AU2021213321A patent/AU2021213321A1/en active Pending
- 2021-01-29 IL IL294850A patent/IL294850A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2021152129A1 (en) | 2021-08-05 |
JP2023532163A (ja) | 2023-07-27 |
MX2022009019A (es) | 2022-08-11 |
KR20220134569A (ko) | 2022-10-05 |
BR112022014772A2 (pt) | 2022-09-20 |
US20230218605A1 (en) | 2023-07-13 |
CA3164700A1 (en) | 2021-08-05 |
EP4096640A1 (en) | 2022-12-07 |
AU2021213321A1 (en) | 2022-08-11 |
CN115279345A (zh) | 2022-11-01 |
IL294850A (en) | 2022-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20220041A7 (es) | Dispersión sólida amorfa de 8-cloro-n-(4-(trifluorometoxi)fenil)quinolin-2-amina | |
CY1114356T1 (el) | Αναστολεις του ιου της ηπατιτιδας c | |
DOP2021000147A (es) | Combinacion terapeutica que comprende lamivudina | |
MA41338A (fr) | Composés de pyrazine pour le traitement de maladies infectieuses | |
CO2019000069A2 (es) | Agentes antivirales contra la hepatitis b | |
BR112018015413A2 (pt) | inibidores de indoleamina-2,3-dioxigenase (ido) | |
CL2021001288A1 (es) | Heterociclos funcionalizados como agentes antivirales | |
EA201792429A1 (ru) | Производные моно- или дизамещенных индолов в качестве ингибиторов репликации вирусов денге | |
PH12019500432A1 (en) | 7-substituted sulfonimidoylpurinone compounds for the treatment and prophylaxis of virus infection | |
MA37712A2 (fr) | Inhibiteurs macrocycliques de virus flaviviridae | |
EA201390538A1 (ru) | Противовирусные соединения | |
BR112018015419A2 (pt) | degradantes seletivos de receptor de estrogênio e os usos dos mesmos | |
WO2011000566A3 (en) | Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections | |
MA42811B1 (fr) | Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
EA201790700A1 (ru) | Моно- или дизамещенные индолы в качестве ингибиторов репликации вирусов денге | |
EA201890722A1 (ru) | Производные моно- или дизамещенных индолов в качестве ингибиторов репликации вирусов денге | |
MA40768A (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
AU2012332832A8 (en) | Compositions useful for the treatment of viral diseases | |
EA201892214A1 (ru) | Замещенные производные индола в качестве ингибиторов репликации вирусов денге | |
UY32721A (es) | Composiciones farmacéuticas útiles para tratar el virus de la hepatitis c (vhc), usos y métodos relacionados | |
UY32457A (es) | Vacuna del virus del dengue inactivado | |
PE20161379A1 (es) | Nuevos compuestos macrociclicos | |
EA202192512A1 (ru) | Пиримидоновые производные с конденсированными кольцами для применения в лечении инфекции, вызванной hbv, или заболеваний, вызванных hbv | |
MX354676B (es) | Compuestos de benzofurano para el tratamiento de infecciones por el virus de hepatitis c (hcv). | |
CU20180035A7 (es) | Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas |